Business Context and Reporting Period
Company: CURIS, INC. (CRIS)
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Curis is a biotechnology company focused on developing emavusertib (CA-4948), an inhibitor of IRAK4 and FLT3, primarily for hematological malignancies. The company operates in a single segment and relies on strategic collaborations, notably with Aurigene Discovery Technologies Limited. In November 2025, the company sold its Erivedge royalty rights, eliminating a previous revenue stream.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
Six Months Ended June 30, 2025 |
|---|---|---|---|
| Revenues, net | $0 | $0 | $5,129 |
| Net Loss | $(8,581) | $(32,780) | $(19,209) |
| Net Loss Per Share (Basic/Diluted) | $(4.02) | $(21.08) | $(36.33) |
| Cash and Cash Equivalents | $5,073 (as of June 30, 2026) | ||
| Total Assets | |||
| Total Liabilities | $14,275 | ||
| Stockholders' Equity | $4,695 | ||
| Accumulated Deficit | $(1,280,161) | ||
| Net Cash Used in Operating Activities | $(18,647) (Six Months 2026) |
Material Changes vs. Prior Period
- Revenue Elimination: Net revenue dropped to $0 for the three and six months ended June 30, 2026, compared to $2.7 million and $5.1 million in the prior year periods. This is due to the November 2025 sale of Erivedge royalty rights to TPC Investments Royalty LLC.
- Increased Net Loss: Net loss for the six months ended June 30, 2026, increased to $32.8 million from $19.2 million in the prior year. This increase was driven primarily by a $11.5 million non-cash loss related to the change in fair value of warrant liabilities from the January 2026 PIPE Financing.
- Expense Reductions: Research and Development (R&D) expenses decreased by 18% year-over-year for the six-month period ($13.2 million vs. $16.0 million), attributed to lower employee-related and clinical costs. General and Administrative (G&A) expenses increased by 10% ($8.3 million vs. $7.5 million) due to costs associated with the January 2026 financing and increased legal fees.
- Capital Structure: The company completed a 1-for-20 reverse stock split in July 2026 (reflected retroactively in share counts). In January 2026, the company raised approximately $18.6 million via a PIPE financing involving convertible preferred stock and warrants.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management has concluded that conditions and events raise substantial doubt about the company's ability to continue as a going concern within one year of the filing date. As of June 30, 2026, cash was $5.1 million. Combined with an estimated $4.8 million net proceeds from an August 2026 public offering, the company expects to fund operations only into the fourth quarter of 2026.
- Unusual Items: The financial results were significantly impacted by the reclassification of warrant liabilities to equity and changes in fair value. Specifically, a $14.5 million loss was recognized upon reclassifying Series A and C warrants to equity, while a $3.1 million gain was recognized on the change in fair value of Series B warrants.
- Outlook: The company expects to continue incurring substantial losses. Future success depends on the clinical progress of emavusertib (specifically the TakeAim CLL and TakeAim Lymphoma studies) and the ability to secure additional capital.
- Risks: Key risks include the inability to raise additional capital, potential delisting from Nasdaq (though compliance with bid price was regained in July 2026), and the uncertainty of clinical trial outcomes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $4.8 million August 2026 offering proceeds to bridge the gap until the next funding round, given the "substantial doubt" disclosure.
- Warrant Liability Volatility: Monitor the fair value of the remaining Series B warrant liability ($600,000 as of June 30, 2026), which is subject to reset features and termination based on clinical milestones (dosing of the fifth patient in the CLL trial).
- Reverse Stock Split Impact: Assess the impact of the 1-for-20 reverse stock split on trading liquidity and compliance with Nasdaq listing requirements.
- Clinical Milestones: Track the progress of the TakeAim CLL Phase 2 study, as the dosing of the fifth patient triggers specific warrant termination conditions.
- Revenue Void: Confirm the company has no near-term revenue sources following the sale of Erivedge royalties, making it entirely dependent on financing and potential future collaborations.